Nasdaq panel grants Avenue Therapeutics extension to May 20, 2024 for listing compliance

AVENUE THERAPEUTICS, INC.

Nasdaq Hearings Panel granted extension through May 20, 2024 to meet stockholders' equity and bid price requirements.
Company must evidence closing bid price >= $1.00 for at least 10 consecutive business days by May 20, 2024.
Previously failed to regain compliance by Nov 15, 2023; delisting process had been stayed pending hearing.
No assurance of regaining compliance; company evaluating all available options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.